Benzinga's Microcap Movers for Monday September 17, 2012
Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:
Shares of Syntroleum (NASDAQ: SYNM), the Tulsa, OK licensor of synthetic liquid hydrocarbon technology, rose 18.06% Monday on 4 times average volume.
Syntroleum reported Monday that the EPA announced an increase to the renewable volume obligation (RVO) for biomass based diesel under RFS2 to 1.28 billion gallons in 2013 from 1.0 billion gallons in 2012.
The renewable diesel produced by Syntroleum's affiliate Dynamic Fuels qualifies as biomass based diesel under the RVO. Renewable diesel is a direct drop-in replacement for petroleum diesel and meets the same ASTM D975 standards. The increased RVO provides the regulatory certainty needed to enable manufacturers of renewable fuels to continue to grow production.
Syntroleum closed at $0.85 on Monday.
Shares ofSavient Pharmaceuticals (NASDAQ: SVNT), the East Brunswick, NJ specialty biopharmaceutical company, rose 13.48% Monday on twice average volume.
Savient Pharmaceuticals was the subject of a positive Seeking Alpha article on Monday.
Savient Pharmaceuticals closed at $2.09 on Monday.
Anthera Pharmaceuticals (NASDAQ: ANTH), the Hayward, CA biopharmaceutical company, rose 13.15% Monday on almost 3 times average volume.
Anthera provided an update Monday on regulatory discussions for the global development of blisibimod. End of Phase 2 discussions with the US Food and Drug Administration (FDA) have been completed and will allow for the submission of Phase 3 protocols and the initiation of registration studies. Earlier in 2012, Anthera received a written response from the European Medicines Agency (EMA) providing similar development feedback for the blisibimod program.
Anthera Pharmaceuticals, closed at $1.05 on Monday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.